Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $171,395.36 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $171,395.36. Following the sale, the insider directly owned 6,007,122 shares of the company’s stock, valued at $7,328,688.84. This trade represents a 2.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Bioventures 2014 L.P. Mpm sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL opened at $1.15 on Friday. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.39. The firm has a market capitalization of $55.82 million, a P/E ratio of -0.71 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 5.30. The company’s fifty day moving average price is $1.60 and its 200 day moving average price is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on HOWL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America cut their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Finally, JMP Securities reduced their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently added to or reduced their stakes in HOWL. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $28,000. Vontobel Holding Ltd. purchased a new stake in shares of Werewolf Therapeutics in the first quarter valued at approximately $34,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the second quarter worth $48,000. Nuveen LLC purchased a new position in Werewolf Therapeutics in the first quarter worth $71,000. Finally, AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the first quarter valued at $79,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.